Article
Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.
The Journal of infectious diseases - 1 Jul 1996
Imrie A, Carr A, Duncombe C, Finlayson R, Vizzard J, Law M, Kaldor J, Penny R, Cooper D A
Abstract excerpt
Human immunodeficiency virus type 1 (HIV-1) variants with reduced in vitro sensitivity to zidovudine, conferred by specific mutations in the viral reverse transcriptase, emerge during prolonged therapy. Late-stage disease and declining CD4 cell count are associated with more rapid emergence of these resistant variants. Isolates of HIV-1 from seroconverters were screened for the zidovudine-resistance marker...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.